PTH and nephrocalcinosis: Phosphorus therapy is associated with diarrhoea and is a stimulant to PTH secretion [13] as well as FGF23 secretion [14]; it is associated with nephrocalcinosis in treated patients with XLH [15] and thus normalisation of serum phosphorus is not the target of therapy in XLH [2].